


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31199982</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1523-6536</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>11</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</Title>
                <ISOAbbreviation>Biol. Blood Marrow Transplant.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Results of Allogenic Hematopoietic Stem Cell Transplantation in Fanconi Anemia due to Bone Marrow Failure; Single Regimen, Single Center Experience of 14 years.</ArticleTitle>
            <ELocationID EIdType="pii" ValidYN="Y">S1083-8791(19)30364-7</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbmt.2019.05.039</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for bone marrow failure (BMF) in patients with Fanconi anemia (FA).</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analyzed the records of FA patients who underwent HSCT with a radiation-free, reduced-intensity conditioning regimen (fludarabine, cyclophosphamide, and anti-thymocyte globulin) along with an unmanipulated graft infusion between 2004 and 2018.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 44 patients underwent HSCT during the study period. Median age at transplantation was 121 months. Regarding the donor source, 22 transplants (50%) were collected from matched related donors (MRD) and 22 transplants (50%) were collected from alternative donors (AD). The median infused CD34+ cell dose was 4.7 × 10<sup>6</sup>/kg (range: 0.8-23) in bone marrow or peripheral blood stem cell recipients and 1.2 × 10<sup>5</sup>/kg (range: 1.1-3.6) in umbilical cord blood recipients. All but 2 patients achieved primary neutrophil engraftment (95%). In a median follow-up of 36 months (range: 1-159), 3-year overall survival was 70.5% in the entire group and 91% in the MRD recipients. Primary causes of death were infections (n=5), acute grade 3-4 graft-versus-host disease (n=4), and hemorrhagic cystitis (n=3). All surviving patients have full (n=29) and acceptable mixed (n=2) donor chimerism and good clinical status.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our results showed an excellent outcome with unmanipulated grafts using a fludarabine-based, radiation-free preparative regimen for MRD recipients. Even though primary neutrophil engraftment rates were good in AD recipients, intervening complications increased mortality in these patients. In clinics where T cell depletion is not feasible, more effort is warranted to improve outcomes for AD recipients.</AbstractText>
                <CopyrightInformation>Copyright © 2019. Published by Elsevier Inc.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gulen</LastName>
                    <ForeName>Tuysuz</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Akdeniz University, Medical Faculty Pediatric Hematology and Oncology Dept.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deniz</LastName>
                    <ForeName>Ozel</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Statistical Consultant Unit of Akdeniz University.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Elif</LastName>
                    <ForeName>Guler</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Akdeniz University, Medical Faculty Pediatric Hematology and Oncology Dept.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kupesiz</LastName>
                    <ForeName>Alphan</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Akdeniz University, Medical Faculty Pediatric Hematology and Oncology Dept.. Electronic address: akupesiz@akdeniz.edu.tr.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>11</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Biol Blood Marrow Transplant</MedlineTA>
            <NlmUniqueID>9600628</NlmUniqueID>
            <ISSNLinking>1083-8791</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">Fanconi Anemia</Keyword>
            <Keyword MajorTopicYN="N">reduced intensity conditioning regimen</Keyword>
            <Keyword MajorTopicYN="N">stem cell transplantation</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>03</Month>
                <Day>08</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>05</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31199982</ArticleId>
            <ArticleId IdType="pii">S1083-8791(19)30364-7</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbmt.2019.05.039</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

